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Background: The use of chromium supplements is widespread for the prevention and treatment of diabetes
mellitus but there are conflicting reports on efficacy, possibly reflecting discrepant effects across different
populations. In the present studies, we test the hypothesis that chromium supplementation raises serum chromium
levels and correspondingly improves insulin sensitivity.
Methods: A double blind placebo-controlled randomized trial was conducted on 31 non-obese, normoglycemic
subjects. After baseline studies, the subjects were randomized to placebo or chromium picolinate 500 μg twice a
day. The primary endpoint was change in insulin sensitivity as measured by euglycemic hyperinsulinemic clamp.
Pre-specified secondary endpoints included fasting lipids, blood pressure, weight, body composition measured by
DXA scan.
Results: After 16 weeks of chromium picolinate therapy there was no significant change in insulin sensitivity
between groups (p=0.83). There was, however, a strong association between serum chromium and change in
insulin resistance (β = -0.83, p=0.01), where subjects with the highest serum chromium had a worsening of insulin
sensitivity. This effect could not be explained by changes in physiological parameters such as body weight, truncal
fat and serum lipids with chromium therapy.
Conclusions: Chromium therapy did not improve insulin sensitivity in non-obese normoglycemic individuals.
Further, subjects who have high serum chromium levels paradoxically had a decline in insulin sensitivity. Caution
therefore should be exercised in recommending the use of this supplement.
Trial registration: The study was registered on the NIH registry (clinicaltrials.gov) and the identifier is NCT00846248Background
Chromium is a very commonly used nutritional supple-
ment. In 1996 it was estimated that about 10 million
people in the United States took chromium supplements
at a cost of $ 150 million dollars per year [1], largely as a
result of claims of beneficial effects on insulin action
and glucose tolerance [2]. The concept that chromium
may have a role in carbohydrate metabolism dates back
to the 1950’s with the observation that rats fed a Torula
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distribution, and reproduction in any mediumthe intolerance was reversed by concentrates prepared
from dried Brewer’s yeast and dried porcine kidney pow-
der. Chromium was identified as the active component
in these concentrates [3]. Limited animal data and some
in vitro data on myoblasts suggested that chromium is a
positive regulator of insulin action [4-7]. In the 1970s
studies of patients with small bowel syndrome suggested
that low chromium levels contributed to glucose intoler-
ance that could be reversed by chromium supplementa-
tion [8-10]. However, the actual contribution of altered
chromium levels to insulin action and glucose homeo-
stasis in humans is not clear.
A recent study of non-diabetic Saudi men and women
reported that insulin resistance in this population wastral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mium. The investigators hypothesized that higher excre-
tion rates could produce chromium deficiencies that
could contribute to insulin resistance [11]. However,
with no measures of serum chromium, it was not pos-
sible to determine whether increased chromium excre-
tion was a primary defect producing reduced serum
chromium, or whether higher excretion resulted from
higher serum levels. The authors nonetheless postulated
that chromium supplementation might be recommended
to prevent or delay the progression of insulin resistance
into diabetes.
Most of the current knowledge on the effects of chro-
mium on glucose homeostasis comes from clinical stud-
ies examining the effect of chromium supplementation
on glucose intolerance and insulin resistance. Results
from these studies have been inconclusive, however,
with both positive and negative findings – reviewed in
[2,12-14]. The presence of multiple confounders in the
study design make these discrepant results difficult to
interpret, and importantly, most studies lacked any
measurement of serum or urine chromium levels. Thus
the ability of physiological variance in serum chro-
mium to impact insulin action and glucose homeosta-
sis in humans remains unclear.
The present studies were performed to test the hy-
pothesis that chromium supplementation would raise
serum chromium levels and correspondingly improve in-
sulin sensitivity. We therefore performed a double blind
placebo controlled clinical trial of chromium picolinate
therapy in a non-diabetic, non-obese population, and
employed the euglycemic hyperinsulinemic clamp to
precisely measure insulin sensitivity. We studied this
population because of the presence of a range of insulin
sensitivities, the likelihood that insulin resistance could
result from multiple factors beyond overt obesity, and
the previously established relationship between insulin




All subjects gave informed consent. The protocols and
consent forms were approved by the University of
California, San Francisco institutional review board
and Clinical Research Center where the study was
conducted.
Subjects
Non-obese, non-diabetic, healthy subjects between the
ages of 20 and 50 were recruited from the local popula-
tion. A body mass index (BMI) cutoff of less than 27
was chosen due to the wide range of insulin sensitivity
values with no correlation to BMI reported for thispopulation [15]. The inclusion cutoff for Asian Americans
was set lower at ≤ 25 because of the increased suscepti-
bility for insulin resistance and type 2 diabetes at lower
BMI values in this population [16]. Women were pre-
menopausal. Individuals with diabetes, cardiovascular
diseases, HIV and other active infections, thyroid disor-
ders, epilepsy, cancer, hepatitis, cystic fibrosis, sickle cell
disease, asthma or renal disease were excluded. Subjects
taking glucocorticoids, adrenergic agonists, psychotropic
drugs, diuretics, beta blockers, HMG CoA reductase
inhibitors, or any other medications known to affect in-
sulin sensitivity, carbohydrate metabolism, or lipid me-
tabolism were excluded.
Exercise and general physical activity pattern were
determined using the questionnaire developed by [17].
This questionnaire generates a physical-activity index
score from 3 to 15 based on work, sport and leisure time
energy expenditure, with each category scored from 1 to
5 (lowest to highest activity level). Subjects with scores
greater than 10 (population mean approximately 8.3)
were not be enrolled in the study.
Subjects underwent a dietary history at enrollment by
the clinical research center nutritionist and were placed
on a weight maintenance diet in order to avoid the con-
founding effect of weight loss on insulin sensitivity. Sub-
jects could not be on nutritional supplements for at least
three months prior to enrollment.
Oral glucose tolerance test
A fasting 75 g oral glucose tolerance test (OGTT) was
performed. Subjects with impaired glucose tolerance or
impaired fasting glucose were excluded.
Euglycemic hyperinsulinemic clamp
A euglycemic hyperinsulinemic clamp [18] was per-
formed at baseline and after 16 weeks treatment with
chromium picolinate or placebo. A primed-continuous
infusion of regular human insulin was administered at a
rate of 40 mU/min/m2 body surface area for 120 min-
utes. This insulin infusion rate is sufficient to suppress
hepatic glucose production in a normal non-obese non-
diabetic population [19,20]. Bedside blood glucose levels
were measured at 5 minute intervals and the glucose
level was maintained at approximately basal level with a
variable infusion of 20% glucose. Glucose disposal values
(M/LBM/I) were calculated as mg glucose infused per
min per kg lean body mass (LBM) during the steady
state period between 90 and 120 minutes divided by
steady state insulin (SSI) levels (in μU/ml x 100).
Blood and urine chemistry
Glucose was determined in whole blood by the glucose
oxidase technique (Sigma). Insulin levels were measured
by ELISA (Millipore, Billerica, MA).
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absorption spectrometry with graphite furnace atomiza-
tion (AAGF) with Zeeman Background Correction and
the serum chromium levels were measured by Induct-
ively Coupled Plasma Mass Spectrometry (ICPMS) with
Collision Cell Technology at Quest Diagnostics Nichols
Institute (Chantilly VA). For AAGF, the sample was
diluted with a “matrix modifier” that helped control the
atomization of Chromium at a specific temperature. For
ICPMS, the sample was diluted with a weak nitric acid
solution. A linear calibration curve was obtained on
blank samples and performed before and after the
assays. Elevated values were repeated with a new sample
set-up to check for contamination issues.
Measurements of body composition indices
Height was measured with a research center stadiometer.
Body weight was recorded. Waist and hip circumferences
were measured by a standardized protocol. Body composi-
tion was assessed by dual-energy X-ray absorptiometry (DXA).
Muscle biopsies
Percutaneous muscle biopsies were obtained from the
belly of the vastus lateralis at time of the euglycemic
hyperinsulinemic clamp. Biopsies were obtained both
prior to and after 120 minutes of insulin infusion on op-
posite legs. After local anesthesia, a 5 mm diameter
Bergstrom needle was passed through a 7 mm skin inci-
sion and subcutaneous tissue, and then advanced ap-
proximately 2 cm beyond the muscle fascia. The biopsy
(75-100 mg tissue) was obtained with applied suction.
The incision was closed with steri-strips and firm pres-
sure applied.
Muscle RNA preparation
RNA was isolated from frozen muscle tissue using the
PureLinkTM RNA mini kit with TRisol Reagent (Invitro-
gen, San Diego, CA). 50 mg of frozen muscle tissue was
homogenized in 1 ml TRisolW Reagent using the Precellys
24TM Homogenizer (Omni International, Kennesaw,
Georgia). Following the tissue homogenization, 0.2 ml
chloroform was added to homogenate, shaken vigor-
ously, incubated at room temperature for 2-3 minutes
and microfuged at 12,000 g for 15 sec. 400 μl of the
clear top layer was transferred to a microfuge tube,
and equal parts of 70% ethanol were added to the tube.
700 μl was loaded onto the PureLink spin cartridge to
purify the total RNA as directed in the PureLink RNA
manual.
Human insulin signaling PCR array
The human insulin signaling pathway PCR array (PAHS-
030A, SA Biosciences/Qiagen) was used to quantify gene
expression in muscle biopsy preparations before andafter chromium therapy in 8 subjects. This array profiles
the expression of 84 genes coding for insulin receptor-
associated proteins (including insulin and receptors,
insulin-like growth factors and receptors, SH3/SH2
adapter protein); PI-3 kinase pathway proteins, MAPK
pathway proteins; primary target proteins for insulin sig-
naling; and target proteins for PPARγ. Each subject was
measured in duplicates both before and after treatment.
The PCR reaction was performed using manufacturer
instructions. Plots of the two technical replicates against
each other as well as hierarchical clustering confirmed
that the reproducibility of the PCR array was very high.
Five housekeeping genes were used: B2M (beta-2-micro-
globulin), HPRT1 (hypoxanthine phosphoribosyltransfer-
ase 1), RPL13A (ribosomal protein L13a), GAPDH
(glyceraldehyde 3- phosphate dehydrogenase) and ACTB
(beta-actin). Based on quality control analyses, we chose
to normalize PCR cycle counts (Ct) of the target cDNAs
such that all arrays have the same average Ct of HPRT1,
RPL13A and ACTB. The normalized cycle counts (ΔCt)
are averaged for each pair of duplicates (ΔCt
*) and gene
expressions are calculated as 2-(ΔCt*).
Chromium or placebo treatment
After completion of baseline tests, subjects were rando-
mized to chromium picolinate or placebo 500 μg twice
daily for 16 weeks and the tests repeated. Both the inves-
tigators and the subjects were blinded. This daily dose of
chromium picolinate was chosen because it was reported
in one study that 1000 μg daily dose had greater efficacy
than a 200 μg daily dose [21]. The chromium picolinate
and placebo were supplied by Nutrition21 Inc. (Pur-
chase, NY 10577). Adherence was assessed by pill count.
We also measured fasting chromium levels in serum and
spot urine at the end of the study.
Statistical analysis
Statistical analyses were performed using PASW 18.0
(SPSS Inc., Chicago, IL, USA). After data cleaning and
checking distributions to assure that all scores met
assumptions, key patient characteristics at baseline were
compared across the chromium and control groups using
chi-square and t-tests. Between-group differences from
pre- to post-assessment on LBM M/I were examined
with a repeated measures ANCOVA (RM-ANCOVA)
analysis controlling for patient characteristics (age, gen-
der, ethnicity, baseline BMI and triglycerides), followed
by pair-wise post-hoc tests. Within the chromium treat-
ment group only, the association between chromium ab-
sorption and change in insulin resistance was examined
in a multiple regression controlling for the same back-
ground patient characteristics. Based on the wide range
of urinary and serum chromium levels, and the assump-
tion that high chromium levels reflect greater chromium
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divided (median split) into a high and low chromium ab-
sorption group. A RM-ANCOVA analysis was repeated
to test the group x time interaction on M LBM/ I be-
tween patients in the placebo group, low chromium
absorbers, and high chromium absorbers. Logistic regres-
sion analyses were used to explore potential baseline pa-
tient measures as predictors of chromium absorption.
Exploratory analyses to test whether pre-post changes in
body weight or composition or lipids were associated
with chromium levels were performed with ANCOVA.
The group sample size of subjects included in the final
data analyses (14 active and 15 placebo) had adequate
power (.80) to detect an effect of f=.30 or higher. This is
equivalent to a medium/large to large effect on insulin
sensitivity and had been previously reported with chro-
mium picolinate therapy [22,23].
Two analyses to test for differential gene expression in
the insulin signaling pathway between before and after
treatment were performed in “R” [24]:
(i) A two-group unpaired Student’s t-test assuming
equal group variances. This is also the test
performed by the online ‘RT2 ProfilerT PCR Array
Data Analysis’ tool provided by the manufacturer.
(ii) A two-group paired Student’s t-test assuming equal
group variances (test not provided by




Age (yrs) 37.23 (10.97) 38
Gender
Male 17 (54.8%) 8 (
Female 14 (45.2%) 7 (
Ethnicity
Non-Hispanic white 18 (58.1%) 7 (
African American 6 (19.4%) 4 (
Asian 5 (16.1%) 4 (
Hispanic 2 (6.5%) 0 (
BMI 23.12 (3.09) 22
Waist circumference (cm) 79.54 (13.05) 78
Fasting Glucose (mmol/L) 4.81 (0.29) 4.4
Total cholesterol (mmol/L) 4.49 (0.13) 4.4
Triglycerides (mmol/L) 0.91 (0.40) 0.8
LDL cholesterol (mmol/L) 2.25 (0.55) 2.1
HDL cholesterol (mmol/L) 1.51 (0.40) 1.6Results
The completed sample consisted of 31 participants (16 in
the chromium group, 15 in the control group). As seen
in Table 1, the mean age of the sample was 37 ± 11 years
and 55% were male. The majority of participants identi-
fied their race as European American/White (58%),
19% as African American, 16% as Asian, and 7% as
Hispanic. The average BMI was 23 ± 3 and average fast-
ing glucose was 4.8 ± 0.3 mmol/l.
Patients in the intervention group did not statistically
differ from the control group on any patient characteris-
tics at baseline (Table 1). The subjects tolerated the
chromium or placebo and there were no adverse reac-
tions reported. Because of previous reports that chro-
mium therapy may impair renal function [25,26],
subjects underwent interval measurements of electro-
lytes and creatinine which were unchanged. After deter-
mining that two subjects in the chromium group did not
comply with taking their chromium as directed (based
on serum and urine chromium levels) they were elimi-
nated from all further analyses, for a total sample of 29
patients (14 in the chromium group and 15 in the con-
trol group). Keeping the two subjects who did not com-
ply with chromium therapy in the analyses did not alter
the conclusions. There was no change in BMI or truncal
fat or lipid levels in response to treatment. Diet and
physical activity as measured by questionnaire stayed
constant throughout the study.cebo Chromium t-test or χ2
15 (48.4%) N=16 (51.6%) p-value
.60 (10.58) 35.94 (11.53) .51
.87
53.5%) 9 (56.3%) –
46.7%) 7 (43.8%) –
.15
46.7%) 11 (68.8%) –
26.7%) 2 (12.5%) –
26.7%) 1 (6.3%) –
0%) 2 (12.5%) –
.68 (2.26) 22.53 (3.74) .45
.7 (6.93) 80.27 (17.15) .75
0 (0.27) 4.55 (0.29) .14
1 (0.86) 4.56 (0.82) .61
2 (0.17) 1.01 (0.53) .21
5 (0.45) 2.34 (0.63) .35
(0.44) 1.43 (0.35) .24
Masharani et al. BMC Endocrine Disorders 2012, 12:31 Page 5 of 10
http://www.biomedcentral.com/1472-6823/12/31Relationship between chromium and insulin sensitivity at
baseline
At baseline, subjects in the placebo group and chro-
mium group had very low urine chromium levels (range
0-0.5 μ/g creatinine) and serum chromium levels (range
<0.5 to 0.6 μg/L). The relation between insulin sensitivity
and both urinary and serum chromium levels was not
statistically significant (r = 0.24, p=0.1; r=0.08, p=0.79
respectively).Changes in insulin sensitivity by chromium absorption
Insulin sensitivity (M LBM/I) did not significantly differ
in the chromium and placebo groups at baseline
(t= -0.22, p=0.83). After 16 weeks of therapy, the mean
change in insulin sensitivity was -1.63 mg/min/kg/mU
insulin (range: -8.9 to + 5.57) in the placebo group
and -1.14 (-5.22 to + 4.11) in the chromium group
(see Figure 1). The group x time interaction was not
significant [F(1,22) = 0.36, p=.54] suggesting the degree
of change in insulin sensitivity from pre- to post-
assessment did not statistically differ by group.Figure 1 Boxplot of pre and post insulin sensitivity as measured by e
placebo group, 1 =chromium group) after 16 weeks of chromium pic
sensitivity. -1.63 mg/min/kg/mU insulin (-8.9 to + 5.57) in the placebo grou
group (p=0.83). The serum chromium levels ranged from less than 0.5 to 1
chromium treated group.Among the chromium treated subjects there was a
wide range of serum and urinary chromium values fol-
lowing treatment. Urine chromium levels ranged from
2.8 to 15.9 μg/g creatinine and the serum chromium
levels ranged from 0.8 to 5.5 μg/L for participants within
the chromium group. Post treatment serum chromium
levels were highly correlated with urine chromium ex-
cretion (r=0.89, p<0.01). Neither serum nor urinary
chromium levels changed in the placebo group (data not
shown). Due to the apparent variation in the degree of
chromium absorption between subjects, we examined
the relationship between serum chromium and change
in insulin resistance. After controlling for baseline pa-
tient characteristics, results of a multiple regression ana-
lysis showed a strong association between serum
chromium and worsening of insulin–mediated glucose
disposal (β = -0.83, p<0.01), where subjects with the
highest serum chromium had a decline in their insulin
sensitivity (Figure 2). To further explore the association
between chromium absorption and insulin resistance,
patients within the chromium group were divided (based
on a medial split at 3.10 μg/L) into a high (n=6) and lowuglycemic hyperinsulinemic clamp (M LBM/I) by group (0 =
olinate versus placebo. There was no significant change in insulin
p and -1.14 mg/min/kg/mU insulin (-5.22 to + 4.11) in the chromium
.0 μg/L in the placebo group and 0.8 to 5.5 μg/L (mean 3.0) in the
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analysis there was a significant time x group inter-
action [F(2, 21) = 3.55, p=0.05]. There were no group
differences at baseline; however, at post-assessment par-
ticipants in the high serum chromium group (> 3.1 μg/L)
were more insulin resistant than participants in the low
serum chromium group (≤ 3.1 μg/L) or the placebo
group (p=0.02, p=0.05 respectively) (Figure 3). Insulin
sensitivity did not differ between the placebo and low
serum chromium groups (p=0.25).
To explore whether the association between chro-
mium absorption level and change in insulin sensitivity
is explained by treatment-mediated changes in other key
variables, we examined associations between chromium
absorption levels with pre- post changes in triglycerides
(F=.48, p=.51), LDL, (F=.07, p=.80) BMI, (F=3.14, p=.13),
and truncal fat (F=1.11, p=.34) and results were non-
significant. Furthermore, when changes in triglycerides,
LDL, BMI, and truncal fat were individually added to
the model, none were independent significant predic-
tors of change in insulin sensitivity, and chromium ab-
sorption remained a significant predictor of reduced
insulin sensitivity in each model. These results suggest,
therefore, a direct effect of chromium on changes in
insulin action that are independent of lipids and
adiposity.Figure 2 Scatterplot of the delta change in insulin sensitivity (M LBM
weeks. High serum chromium levels are associated with increase in insulinPredictors of chromium absorption
In exploratory analyses, we examined potential baseline
predictors of high vs. low chromium absorption (among
only patients in the chromium group) with logistic re-
gression analysis. While no baseline variables reached
statistical significance, the largest effects were for partici-
pants who were older (OR=1.09, p=0.17), those with
lower triglycerides (OR=0.95, p=0.18), and those with
lower levels of homocysteine (OR=0.38, p=0.13) to have
a greater likelihood of being in the high absorption
group.
Human insulin signaling PCR array analysis
In order to explore the possibility that high serum chro-
mium levels could have a direct effect on skeletal
muscle, the primary site for insulin-mediated glucose
disposal, we analyzed skeletal muscle biopsies from 4
subjects who had high serum chromium levels and be-
came insulin resistant and 4 subjects who had lower
serum chromium levels and had no change in insulin
sensitivity. Differential expression of genes in the insulin
signaling pathway was explored for high- and low-
chromium subjects by PCR array as evidence for a direct
impact of chromium on skeletal muscle.
At a 1% significance level, both unpaired and paired
analyses failed to identify any significant change in/I) chromium group against fasting serum chromium levels at 16
resistance, r=0.85, p=0.01.
Figure 3 Boxplot of the delta change in insulin sensitivity (M LBM/I by group: Chromium therapy group is divided into high serum
chromium group (>3.1 μg/L); low serum chromium group (≤ 3.1 μg/L); and placebo group. High serum chromium group had had greater
insulin resistance than participants in the low serum chromium group or the placebo group, p=0.02, p=0.05 respectively.
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chromium therapy.Discussion
We studied the effect of chromium picolinate on
insulin-stimulated glucose uptake in a well-characterized
population of non-obese non-diabetic subjects. We did
not find evidence that serum chromium levels had a sig-
nificant impact on insulin sensitivity in this population,
nor did we find evidence that high chromium excretion
was associated with insulin resistance. In investigating
the use of daily chromium picolinate supplementation as
a modulator of insulin action, we could find no evidence
for a beneficial effect of this compound. Our principal
finding was that those subjects with the highest levels of
serum chromium following treatment had worsening of
insulin sensitivity rather than an improvement. This
negative effect of chromium supplementation was high-
lighted when we divided the chromium treated subjects
into two groups using the medial serum chromium value
of 3.1 μg/L – the subjects with the higher chromium
levels had greater reduction in insulin sensitivity than
the lower chromium levels. There were no obvious base-
line characteristics that identified individuals who were
likely to have greater serum levels of chromium. Theincrease in insulin resistance could not explained by
weight gain or alterations in lipid levels.
While claims of benefits of chromium therapy on
weight loss and increased muscle mass have been largely
discredited [2,27], this supplement is still being pro-
moted for its beneficial effects on insulin action and glu-
cose tolerance [2]. In the 1970’s and 1980’s there were
three clinical reports of [8-10] of patients with small
bowel loop syndromes on parental nutrition who devel-
oped glucose intolerance and who improved following
chromium therapy. These case reports led to the routine
addition of chromium to TPN solutions. They also pro-
vided impetus for other clinical studies (see reviews
[2,12,13]) of chromium therapy in normal subjects,
people with glucose intolerance, and people with dia-
betes (both type 1 and type 2) [21-23,28-46]. The results
have been inconclusive, with some studies reporting a
positive effect on glucose and/or insulin levels whereas
others failing to show benefit. Design problems include
open label studies [22,30,35,39]; some studies including
subjects with different disorders s e.g. type 1 and type 2
patients [30,34]; type 2 subjects remaining on drugs that
affect insulin secretion or insulin action [35,39,47]; inad-
equate control of confounders such as hyperglycemia
and obesity that affect insulin action [22]; and failure to
address the role of chromium levels on the measured
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studies is their use of surrogate measures such as fasting
insulin and glucose tolerance tests which may not be
sensitive enough to assess changes in insulin action with
therapy. Very few studies employed the more accurate
euglycemic hyperinsulinemic clamp technique to assess
insulin action [23,42]. The studies also used a wide range
of chromium doses, formulations and durations of ther-
apy. Supplementation with 200 to 1000 μg of chromium
picolinate has been reported to improve glucose intoler-
ance and lower circulating insulin levels [21,48] with one
study in type 2 diabetes patients showing a greater im-
provement with 1000 μg dose compared to 200 μg dose
[21]. The 1000 μg daily has been used in a number of
other clinical studies [28,29] and not associated with any
toxic effects.
We have addressed many of these limitations in the
present study. The subjects had normal glucose intoler-
ance and were of normal weight. The absence of obesity
and hyperglycemia removes two important confounders
that can affect insulin action. We also measured serum
and urine chromium levels to confirm compliance and
also to assess effects of chromium levels on the mea-
sured parameters. We used the euglycemic hyperinsuli-
nemic clamp rather than surrogate measures to assess
insulin action before and after therapy. We also used
chromium picolinate at a dose that previously had been
reported to improve insulin resistance.
We did not observe an increase in insulin sensitivity in
the treatment group, but observed a decrease in insulin
sensitivity only in subjects who had high levels of serum
or spot urinary chromium levels. Generally, the absorp-
tion of chromium picolinate has reported to be very low
in the range of 2.8 ±1.14% (SD) but there is significant
individual variation with peak urinary excretion varying
5 fold after acute dosing [49]. Distribution studies with
labeled chromium also suggest that trivalent chromium
is stored in the body principally in the liver and also in
kidneys, spleen and muscle [2] and it is possible that the
impact of chromium therapy may only become apparent
in studies lasting several months.
In order to further explore the mechanism by which
chromium picolinate induces insulin resistance, we used
a human insulin signaling pathway PCR array to exam-
ine the expression of genes in skeletal muscle before and
after chromium therapy. We were unable to demon-
strate any changes in gene expression with therapy in 4
subjects who became insulin resistant with therapy. The
expression array examines only the genes coding for
proteins that have been directly implicated in, or affected
by, insulin signaling. It is of course possible that chro-
mium therapy affects the expression of other genes that
were not studied; or that chromium affects muscle insu-
lin signaling at the level of protein function, without animpact on expression of insulin-sensitive genes, through
actions that may or may not originate in skeletal
muscle. Proposed targets for chromium action include
membrane phosphotyrosine phosphatase [50], insulin
receptor tyrosine kinase [51], protein-tyrosine phos-
phatase 1B [52].
Some additional limitations of our study need to be
discussed. The original study was designed to evaluate
group differences (placebo vs. chromium therapy) and
not powered to examine subgroups (serum chromium
levels). The results therefore should be viewed with
some caution and need to be replicated. We restricted
our recruitment to normoglycemic and non-obese sub-
jects and it remains possible that people with glucose in-
tolerance or frank diabetes may respond differently, due
to effects of chromium on insulin secretion or glucose
toxicity. Our subjects were healthy eating a normal diet
and so were not chromium deficient. It is quite possible
as noted in the case reports of short bowel syndrome
patients on TPN in the 1970’s that extreme chromium
deficiency causes defects in insulin secretion and/or ac-
tion. The concept that extreme deficiency or excess of
an agent can have the same clinical effect is not without
precedence. Both magnesium deficiency and excess inhi-
bits parathyroid hormone secretion resulting in hypocal-
cemia; and the hypocalcemia due to deficiency is
corrected by magnesium supplements.Conclusions
In conclusion, pharmacological doses of chromium pico-
linate therapy do not improve insulin sensitivity in nor-
mal non-diabetic subjects. Indeed, it appears that
subjects for whom chromium supplementation produced
high serum chromium levels paradoxically had a wor-
sening of their insulin sensitivity. We do not have infor-
mation regarding the mechanism by which high serum
chromium levels decreases insulin sensitivity. We can
say that it is unlikely to be due changes in expressions of
genes that have been identified to be involved in the in-
sulin signaling pathway.
If this finding of worsening insulin sensitivity with
high serum chromium levels is confirmed then it is pos-
sible that the widespread use of chromium supplements
may be contributing to, rather than ameliorating, insulin
resistance in the population.Competing interests
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